The protein deacetylase SIRT2 exerts metabolic control over adaptive β cell proliferation

Matthew Wortham1,2, Bastian Ramms1, Chun Zeng1

  • 1Departments of Pediatrics and Cellular and Molecular Medicine, Pediatric Diabetes Research Center, UCSD, La Jolla, California, USA.

Insights

Scientists discovered that inhibiting Sirtuin 2 (SIRT2) in pancreatic beta cells promotes controlled beta cell proliferation during hyperglycemia, offering a potential diabetes therapy. This approach preserves feedback control, preventing excessive cell growth.

Area of Science:

  • Endocrinology and Metabolism
  • Cell Biology
  • Molecular Medicine

Background:

  • Therapies for diabetes aim to expand endogenous pancreatic beta cells while maintaining feedback control.
  • Excessive beta cell proliferation must be avoided to prevent complications.
  • Identifying regulators of beta cell proliferation is crucial for developing safe and effective treatments.

Purpose of the Study:

  • To identify regulators of beta cell proliferation that allow for controlled expansion.
  • To investigate the role of Sirtuin 2 (SIRT2) in regulating beta cell mass.
  • To explore a novel therapeutic strategy for increasing beta cell mass in diabetes.

Main Methods:

  • Genetic deletion of Sirt2 in mouse beta cells.
  • Analysis of beta cell proliferation under homeostatic and hyperglycemic conditions.
  • Inhibition of SIRT2 in human islets and analysis of acetylated proteins.
  • Transcriptomic analysis of Sirt2-inactivated beta cells.
  • Systemic administration of GLP1-coupled Sirt2-targeting antisense oligonucleotide in mice.

Main Results:

  • Sirt2 deletion in mouse beta cells increased proliferation during hyperglycemia but not under homeostatic conditions, preserving feedback control.
  • SIRT2 was found to restrain proliferation in human islet beta cells, indicating conserved function.
  • SIRT2 inhibition affected enzymes involved in oxidative phosphorylation and altered the interpretation of hyperglycemia as a stress.
  • Systemic administration of an antisense oligonucleotide successfully inactivated SIRT2 in beta cells, stimulating proliferation during hyperglycemia.

Conclusions:

  • Sirtuin 2 (SIRT2) acts as a key regulator that restrains beta cell proliferation.
  • Inactivating SIRT2 offers a therapeutic strategy to increase beta cell mass in diabetes without disrupting feedback control mechanisms.
  • Further research is needed to validate these findings in human beta cells from diabetic and non-diabetic individuals.

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K
Cell Specific Gene Expression01:58

Cell Specific Gene Expression

Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Regulation of Metabolism01:19

Regulation of Metabolism

Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
9.9K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.6K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.4K